IOSP vs. ALB, CE, BCPC, NEU, FUL, ASH, SXT, KWR, MTX, and SCL
Should you be buying Innospec stock or one of its competitors? The main competitors of Innospec include Albemarle (ALB), Celanese (CE), Balchem (BCPC), NewMarket (NEU), H.B. Fuller (FUL), Ashland (ASH), Sensient Technologies (SXT), Quaker Chemical (KWR), Minerals Technologies (MTX), and Stepan (SCL). These companies are all part of the "specialty chemicals" industry.
Innospec vs.
Innospec (NASDAQ:IOSP) and Albemarle (NYSE:ALB) are both mid-cap basic materials companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, community ranking, earnings, analyst recommendations, dividends and valuation.
Innospec pays an annual dividend of $1.58 per share and has a dividend yield of 1.5%. Albemarle pays an annual dividend of $1.62 per share and has a dividend yield of 2.0%. Innospec pays out 111.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Albemarle pays out -14.5% of its earnings in the form of a dividend. Albemarle has increased its dividend for 30 consecutive years. Albemarle is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Albemarle received 444 more outperform votes than Innospec when rated by MarketBeat users. However, 66.20% of users gave Innospec an outperform vote while only 62.31% of users gave Albemarle an outperform vote.
96.6% of Innospec shares are held by institutional investors. Comparatively, 92.9% of Albemarle shares are held by institutional investors. 1.5% of Innospec shares are held by insiders. Comparatively, 0.4% of Albemarle shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Innospec has higher earnings, but lower revenue than Albemarle. Albemarle is trading at a lower price-to-earnings ratio than Innospec, indicating that it is currently the more affordable of the two stocks.
Albemarle has a consensus price target of $109.68, suggesting a potential upside of 35.12%. Given Albemarle's stronger consensus rating and higher possible upside, analysts plainly believe Albemarle is more favorable than Innospec.
In the previous week, Innospec and Innospec both had 15 articles in the media. Innospec's average media sentiment score of 0.87 beat Albemarle's score of -0.35 indicating that Innospec is being referred to more favorably in the media.
Innospec has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500. Comparatively, Albemarle has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.
Innospec has a net margin of 1.93% compared to Albemarle's net margin of -21.93%. Innospec's return on equity of 12.27% beat Albemarle's return on equity.
Summary
Innospec and Albemarle tied by winning 10 of the 20 factors compared between the two stocks.
Get Innospec News Delivered to You Automatically
Sign up to receive the latest news and ratings for IOSP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innospec Competitors List
Related Companies and Tools
This page (NASDAQ:IOSP) was last updated on 2/21/2025 by MarketBeat.com Staff
Free IOSP Stock Alerts